ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K as a foreign private issuer for September 2021. The filing is dated September 9, 2021, and identifies the company’s principal executive office in Epalinges, Switzerland.
The filing incorporates Exhibit 99.1, described only as a press release dated September 9, 2021. The press release text is not included in the provided filing content.
Financial and operating metrics
The provided filing text does not contain revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other quantitative financial metrics.
Material changes versus the prior comparable period
The filing text does not provide information on material changes compared with a prior period.
Guidance, outlook, risks, contingencies, and unusual items
The filing text does not provide guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items. Any such information may be contained in Exhibit 99.1, which is not included in the source text.
Key facts for investor verification
- Obtain and review Exhibit 99.1, the September 9, 2021 press release.
- Verify whether the exhibit contains financial results, clinical or regulatory updates, guidance, or other material disclosures.
- Confirm any financial or operating figures directly against the company’s applicable Form 20-F or subsequent reports.